Gracell Biotechnologies Stock Cash And Equivalents

Gracell Biotechnologies fundamentals help investors to digest information that contributes to Gracell Biotechnologies' financial success or failures. It also enables traders to predict the movement of Gracell Stock. The fundamental analysis module provides a way to measure Gracell Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gracell Biotechnologies stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Gracell Biotechnologies Company Cash And Equivalents Analysis

Gracell Biotechnologies' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

 = 

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current Gracell Biotechnologies Cash And Equivalents

    
  1.71 B  
Most of Gracell Biotechnologies' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gracell Biotechnologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Competition

In accordance with the recently published financial statements, Gracell Biotechnologies has 1.71 B in Cash And Equivalents. This is 108.31% higher than that of the Biotechnology sector and 282.45% higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 36.72% higher than that of the company.

Gracell Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gracell Biotechnologies' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gracell Biotechnologies could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics of similar companies.
Gracell Biotechnologies is currently under evaluation in cash and equivalents category among its peers.

Gracell Fundamentals

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Consideration for investing in Gracell Stock

If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format